CoChat

Characterization of SGN-CD123A, A Potent CD123-Directed Antibody–Drug Conjugate for Acute Myeloid Leukemia

Li, Fu, Sutherland, May Kung, Yu, Changpu, Walter, Roland B., Westendorf, Lori, Valliere-Douglass, John, Pan, Lucy, Cronkite, Ashley, Sussman, Django, Klussman, Kerry, Ulrich, Michelle, Anderson, Martha E., Stone, Ivan J., Zeng, Weiping, Jonas, Mechthild, Lewis, Timothy S., Goswami, Maitrayee, Wang, Sa A., Senter, Peter D., Law, Che-Leung, Feldman, Eric J., Benjamin, Dennis R. · 2018 · Molecular Cancer Therapeutics
Cited by 102

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Treatment choices for acute myelogenous leukemia (AML) patients resistant to conventional chemotherapies are limited and novel therapeutic agents are needed. IL3 receptor alpha (IL3Rα, or CD123) is expressed on the majority of AML blasts, and there is evidence that its expression is increased on leukemic relative to normal hematopoietic stem cells, which makes it an attractive target for antibody-based therapy. Here, we report the generation and preclinical characterization of SGN-CD123A, an antibody–drug conjugate using the pyrrolobenzodiazepine dimer (PBD) linker and a humanized CD123 antibody with engineered cysteines for site-specific conjugation. Mechanistically, SGN-CD123A induces activation of DNA damage response pathways, cell-cycle changes, and apoptosis in AML cells. In vitro, SGN-CD123A–mediated potent cytotoxicity of 11/12 CD123+ AML cell lines and 20/23 primary samples from AML patients, including those with unfavorable cytogenetic profiles or FLT3 mutations. In vivo, SGN-CD123A treatment led to AML eradication in a disseminated disease model, remission in a subcutaneous xenograft model, and significant growth delay in a multidrug resistance xenograft model. Moreover, SGN-CD123A also resulted in durable complete remission of a patient-derived xenograft AML model. When combined with a FLT3 inhibitor quizartinib, SGN-CD123A enhanced the activity of quizartinib against two FLT3-mutated xenograft models. Overall, these data demonstrate that SGN-CD123A is a potent antileukemic agent, supporting an ongoing trial to evaluate its safety and efficacy in AML patients (NCT02848248). Mol Cancer Ther; 17(2); 554–64. ©2017 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1535-7163.mct-17-0742

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 102

Metadata

Authors
Li, F., Sutherland, M. K., Yu, C., Walter, R. B., Westendorf, L., Valliere-Douglass, J., Pan, L., Cronkite, A., Sussman, D., Klussman, K., Ulrich, M., Anderson, M. E., Stone, I. J., Zeng, W., Jonas, M., Lewis, T. S., Goswami, M., Wang, S. A., Senter, P. D., Law, C.-L., Feldman, E. J., & Benjamin, D. R.
Venue
Molecular Cancer Therapeutics
Published
2018-02-01
Volume
17
Issue
2
Pages
554-564
ISSN
  • 1535-7163 (ISSN-L)
  • 1538-8514
OpenAlex
W2768799228
Cited by
102
References
2
FWCI
9.05
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Characterization of SGN-CD123A, A Potent CD123-Directed Antibody–Drug Conjugate for Acute Myeloid Leukemia. https://app.cochat.ai/papers/10.1158/1535-7163.mct-17-0742
The paper
Li, F., Sutherland, M. K., Yu, C., Walter, R. B., Westendorf, L., Valliere-Douglass, J., Pan, L., Cronkite, A., Sussman, D., Klussman, K., Ulrich, M., Anderson, M. E., Stone, I. J., Zeng, W., Jonas, M., Lewis, T. S., Goswami, M., Wang, S. A., Senter, P. D., . . . Benjamin, D. R. (2018). Characterization of SGN-CD123A, A Potent CD123-Directed Antibody–Drug Conjugate for Acute Myeloid Leukemia. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-17-0742

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.